Cybin
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Cybin and buy or sell other stocks, ETFs, and their options commission-free!About CYBN
Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.
CEOEric So
CEOEric So
Employees50
Employees50
HeadquartersToronto, Ontario
HeadquartersToronto, Ontario
Founded2016
Founded2016
Employees50
Employees50
CYBN Key Statistics
Market cap187.15M
Market cap187.15M
Price-Earnings ratio-1.87
Price-Earnings ratio-1.87
Dividend yield—
Dividend yield—
Average volume1.05M
Average volume1.05M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$10.72
52 Week high$10.72
52 Week low$4.81
52 Week low$4.81
Stock Snapshot
Cybin(CYBN) stock is priced at $7.17, giving the company a market capitalization of 187.15M. It carries a P/E multiple of -1.87.
On 2026-01-08, Cybin(CYBN) shares started trading at —, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 1.05M.
The stock's 52-week range extends from a low of $4.81 to a high of $10.72.
The stock's 52-week range extends from a low of $4.81 to a high of $10.72.
People also own
Based on the portfolios of people who own CYBN. This list is generated using Robinhood data, and it’s not a recommendation.